Baicalein has been identified as an inhibitor of Lyn kinase [27], which is the first signal-transducing kinase required for B cell activation in SSc patients [28] and contributes to the development of systemic autoimmunity and skin sclerosis through CD19-dependent pathway in tight skin mice [29]. Here, CD19 is linked to systemic sclerosis.